ANVS
Annovis Bio IncNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$66.64M
P/E Ratio
—
EPS
$-1.40
Beta
1.36
52W High
$5.50
52W Low
$1.11
50-Day MA
$2.53
200-Day MA
$2.73
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Annovis Bio Inc
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -220.60% |
| Return on Assets | -106.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.62 |
| Price-to-Book | 3.84 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $28.36M |
| Float | $24.26M |
| % Insiders | 14.44% |
| % Institutions | 18.66% |
Analyst Ratings
Consensus ($12.50 target)
1
Strong Buy3
BuyData last updated: 4/7/2026